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I~  Clinical pharmacology study of a new tobramycin solution for 
nebulisation 
G. Poli 1 , D. Acerbi 1 , R. Pennini 1, A. Soliani Raschini 1, F. Bianco 1 , M. Corrado 2, 
G. Eichler 3, I. Eichler 3. 1R&D, Chiesi Farmaceutici S.p.A., Parma, Italy; 2Clinical 
Research, Cross S A., Arzo, Switzerland; 3Clinical Pharmacology, AKH, Vienna, 
Austria 
Aim: to characterise the in vitro and in vivo performance of Bramitob ®, a new 
tobramycin preservative-free sterile solution for nebulisation in comparison with 
ToN ® . 
Methods: in-vitro measurements, nebulisation time and the emitted ose, respirable 
dose, fine particle fraction and mass median aerodynamic diameter, were carried 
out using Pari Turbo Boy ® and Systam 290 LS ® nebulizers. The in vivo study 
was carried out as a single centre, single dose, randomised, double blind, two- 
way crossover study. Systemic exposure in plasma to assess the relative risk for 
systemic side effects and sputum levels as surrogate biomarker of activity were 
evaluated in nine CF patients after inhalation of Bramitob ® 300 rag/4 mL, or Tobi ® 
300 rag/5 mL. 
Results: In vitro data demonstrated the equivalent performance of Bramitob ® and 
ToN ® with both nebulizers. 
In CF patients, tobramycin plasma levels peaked at 1.2 h (median) with Tobi ® 
and 1.5 h with Bramitob ®. Cmax and AUCoo (geometric mean) were 540ng/mL 
and 3454 ng*h/mL with Tobi ® and 549 ng/mL and 3470 ng*h/mL with Bramitob ®. 
Maximum tobramycin concentrations (543gg/g for ToN ® and 814gg/g for 
Bramitob ®) were observed in the first sputum sample taken 0.25 h after nebu- 
lisation. The target obramycin sputum concentration of 400 gg/g was reached in 
eight patients with Bramitob ® and five patients with ToN ®. 
Conclusions: The in-vitro results demonstrates the similar performances of 
Bramitob ® and ToN ®. In the in vivo study, the systemic bioavailability of to- 
bramycin was comparable with both formulations, whereas the peak concentration 
in sputum was higher with Bramitob ® than with ToN ®. 
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1~ Diagnostic value of Pseudomonas aeruginosa antibodies in 
Cystic Fibrosis 
F. Ratjen 1, H. Walter 2, M. Haug 2, C. Meisner 3, H. Grasemann 1 , G. DSring 2. 
1 Children 2' Hospital, University of Duisburg-Essen, 2Institute of Medical 
Microbiology and Hygiene, 3Institute for Medical Injbrmation Processing, 
Universitdtsklinikum, University of Tiibingen, Tiibingen, Germany 
Background: Specific serum antibodies may be helpful in defining the status of 
Pseudomonas aeruginosa infection in cystic fibrosis (CF) and to follow the response 
of patients to treatment. 
Methods: P aeruginosa antibodies, directed against alkaline proteinase (AP), 
elastase (ELA) and exotoxin A (ExoA) were assessed by ELISA in 1,791 serum 
samples of 375 European CF patients. 
Results: At a specificity of 97.5%, the sensitivity was highest for antibodies against 
AP (85.4%), followed by ELA (76.2%) and ExoA (72.0%). AR ELA or ExoA 
antibody titres were significantly higher (p < 0.05) in patients chronically infected 
with P aeruginosa versus patients with negative cultures. The sensitivity of the 
combined three ELISAs was higher than that for any single ELISA alone, Positive 
serum antibody titers against at least one of the three antigens were present before, 
simultaneously and after R aeruginosa culture in 62.2%, 16.2% and 21.6% of the 
patients, respectively. Longitudinal assessment of antibody titres in 43 CF patients 
receiving "early eradication therapy" revealed a significant decrease in antibody 
titres against AP and ExoA. 
Conclusion: Antibody testing against AR ELA and ExoA is useful to define the 
status ofR aeruginosa infection in CF patients and to follow the response of patients 
to treatment. 
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isolation of Pseudomonas aeruginosa 
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Objective: Between 1985 and 1999, after first isolation ofPseudomonas eruginosa 
(P ae), patients of our centre either were treated antibiotically or not, depending on 
the clinical presentation. Goal was to describe the impact of the initial procedure 
on long-term outcome. 
Methods: Retrospective chart review of 392 CF patients attending our centre 
between 1985 99. Variables: Therapy against P ae within the first year after 
detection, FEV1, frequency of P ae during the observation period. 
Patients: 172 patients were observed >5 years and showed at least one P ae positive 
culture (mean age at first P ae detection 9.14 years, range 0.6 30.4) and were 
differentiated in "no therapy" (n 83) and "therapy" (n 89) which included oral + 
inhaledn 6, oral+inhaled+intravenousn 19, intravenousn 25, inhaledn 39. 
Results: FEV1 differed significantly between the two groups at the time of first P 
ae detection (p 0.01) but not after 5 and 10 years. FEV1 declined in "no therapy" 
(p 0.037 after 5, p 0.014 after 10 years), but not in "therapy". Subgroup analysis 
showed best results for inhaled or intravenous therapy. Further isolation of P ae in 
both groups was equal within the first year (positive: 69 vs 74 patients) and for the 
complete observation period (positive: 72% of 2729 vs 74% of 3473 cultures). 
FEV1 (% predicted) at beginning at~er 5 years after 10 years 
"No therapy" (n) 92±21 (66) 84±21 (80) 83±23 (75) 
"Therapy" (n) 82±24 (76) 81±24 (83) 76±25 (80) 
Mean ± standard eviation, Mann-Whitney Test, p < 0.05 significant. 
Conclusion: In "no therapy", patients initially were healthier, but had a decline of 
FEV1 in the long-run. Initially not treated patients in the first instance were sicker, 
however subsequently had less deterioration of FEV1. 
• Combining microbiological culture, PCR and serology increases 
Pseudomonas aeruginosa diagnosis in CF 
EVE da Silva Filho 1'2, A.F. Tateno 2, K.M. Martins 1, A.C.G.S. Azzuz 3, 
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Aims: The diagnosis of B aeruginosa by microbial culturing (MC) may yield 
false-negative r sults in CE Here we assessed the diagnostic value of PCR and 
serology (S). 
Methods: Oropharyngial specimens (OS), sputum and blood specimens were 
collected from 87 Brazilian CF patients. OS were kept on transport medium 
and sputum samples were diluted in PBS and homogenized by vortexing until 
cultivation for the detection of B aeruginosa on selective media using routine 
methods. PCR was carried out by targeting a 520 bp portion of the B aeruginosa 
GDP mannose dehydrogenase g ne algD. B aeruginosa ntibodies, directed against 
alkaline proteinase (AP), elastase (ELA) and exotoxin A (ExoA) were assessed by 
ELISA in serum samples. 
Results: In 42 not sputum producing patients (median age: 5.5 y) S, MC and PCR 
gave positive results in 33%, 36% and 50%, respectively. Combination of MC and 
PCR detected B aeruginosa in 60% of patients, whereas combination of all three 
methods revealed 62% of patients positive. B aeruginosa was diagnosed in 53%, 
60% and 71% of 45 patients producing sputum (median age: 12.6 y) by S, MC 
and PCR, respectively. When MC and PCR were combined, B aeruginosa was 
detectable in 71% of patients, whereas combination of all three methods revealed 
78% of patients positive for the pathogen. 
Conclusion: The combination of MC, PCR and S is useful to define the status of 
P aeruginosa infection in CF patients. 
